. Author manuscript; available in PMC: 2017 Oct 31.

Published in final edited form as: J Biomed Mater Res A. 2013 Dec 12;102(11):4182–4194. doi: 10.1002/jbm.a.35052

TABLE II.

Intravenous Hemostatic Agents

Platform	Targeting Moiety	Discussion
Red Blood Cell	Fibrinogen,¹⁴¹ fibrinogen mimicking peptide¹⁴²	Biologically derived, viral transmission risk, autologous red blood cells investigated, high cost, and low stability
Albumin	Fibrinogen,^144,145 fibrinogen γ-chain dodecapeptide¹⁴⁶	Crosslinked albumin particles, viral transmission risk, and lower cost than red blood cell derived
Liposome	Red blood cell and platelet proteins,¹⁴⁷ fibrinogen mimicking peptide,¹⁴⁸ fibrinogen γ-chain dodecapeptide,¹⁴⁹ fibrinogen mimicking peptide, collagen binding peptide, and von Willebrand factor binding peptide^150,151	Earlier approaches still used biologically derived components, later iterations used multiple nonbiologically derived targeting mechanisms, issues with cost and scalability
PLGA	Fibrinogen mimicking peptide,^152–154 fibrinogen γ-chain dodecapeptide¹⁵⁵	Synthetic and degradable, nonspherical morphologies investigated, issues with cost and scalability